Group 1 - The stock of Jinkai Biological Science (301509) closed at 26.71 yuan, with a decline of 6.87%, currently in a state of breaking issue [1] - Jinkai Biological Science was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on August 3, 2023, with an issuance of 21,508,335 shares, accounting for 25.00% of the total shares post-issuance, at a price of 56.56 yuan per share [1] - The total amount raised from the issuance was 1,216.5114 million yuan, with a net amount of approximately 1,110.7443 million yuan after deducting issuance costs, exceeding the original plan by 310.7443 million yuan [1] Group 2 - The company plans to use the raised funds for pharmaceutical intermediates, a project for producing 190 tons of high-end pharmaceutical products, and to supplement working capital [1] - The total issuance costs (excluding VAT) amounted to 105.7671 million yuan, with CITIC Securities receiving 86.5456 million yuan as underwriting and sponsorship fees [1] - The actual controllers of Jinkai Biological Science are FUMINWANG and LIANPINGWU, both holding U.S. nationality [1] Group 3 - The company's 2023 annual equity distribution plan includes a cash dividend of 8.00 yuan for every 10 shares and a capital reserve increase of 4.00 shares for every 10 shares [2] - The record date for the equity distribution is set for May 8, 2024, with the ex-dividend date on May 9, 2024 [2]
金凯生科跌6.87% 2023年上市超募3.1亿中信建投保荐